- Home
- XENE vs ICUI Comparison
XENE vs ICUI Comparison
Compare XENE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- ICUI
- Stock Information
- Founded
- XENE 1996
- ICUI 1984
- Country
- XENE Canada
- ICUI United States
- Employees
- XENE N/A
- ICUI N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- ICUI Medical/Dental Instruments
- Sector
- XENE Health Care
- ICUI Health Care
- Exchange
- XENE Nasdaq
- ICUI Nasdaq
- Market Cap
- XENE 3.2B
- ICUI 3.2B
- IPO Year
- XENE 2014
- ICUI 1992
- Fundamental
- Price
- XENE $43.87
- ICUI $152.46
- Analyst Decision
- XENE Strong Buy
- ICUI Buy
- Analyst Count
- XENE 11
- ICUI 6
- Target Price
- XENE $53.55
- ICUI $183.60
- AVG Volume (30 Days)
- XENE 782.5K
- ICUI 314.7K
- Earning Date
- XENE 11-03-2025
- ICUI 11-06-2025
- Dividend Yield
- XENE N/A
- ICUI N/A
- EPS Growth
- XENE N/A
- ICUI N/A
- EPS
- XENE N/A
- ICUI N/A
- Revenue
- XENE $7,500,000.00
- ICUI $2,320,363,000.00
- Revenue This Year
- XENE N/A
- ICUI N/A
- Revenue Next Year
- XENE $207.88
- ICUI N/A
- P/E Ratio
- XENE N/A
- ICUI N/A
- Revenue Growth
- XENE N/A
- ICUI N/A
- 52 Week Low
- XENE $26.74
- ICUI $107.00
- 52 Week High
- XENE $44.23
- ICUI $175.51
- Technical
- Relative Strength Index (RSI)
- XENE 68.37
- ICUI 74.65
- Support Level
- XENE $39.09
- ICUI $131.99
- Resistance Level
- XENE $42.31
- ICUI $138.48
- Average True Range (ATR)
- XENE 1.48
- ICUI 6.36
- MACD
- XENE 0.31
- ICUI 1.42
- Stochastic Oscillator
- XENE 99.40
- ICUI 96.21
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.